Firsocostat + Fenofibrate
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis (NASH)
Conditions
Nonalcoholic Steatohepatitis (NASH)
Trial Timeline
Sep 23, 2016 → May 13, 2019
NCT ID
NCT02891408About Firsocostat + Fenofibrate
Firsocostat + Fenofibrate is a phase 1 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT02891408. Target conditions include Nonalcoholic Steatohepatitis (NASH).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02891408 | Phase 1 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis (NASH)